Publications

A selected list of our team publications

Livitz, Kristen Stevenson, Laura Rassenti, Daniel Rosebrock et al. "Growth dynamics in naturally progressing chronic lymphocytic leukaemia." Nature 570, no. 7762 (2019): 474-479.

"Each growth pattern was associated with marked differences in genetic composition, the pace of disease progression and the extent of clonal evolution. ... we found that dynamic changes in the disease course of CLL were shaped by the genetic events that were already present in the early slow-growing stages. Finally, by analysing the growth rates of subclones compared with their parental clones, we quantified the growth advantage conferred by putative CLL drivers in vivo."

Parikh, Aparna R., Ignaty Leshchiner, Liudmila Elagina, Lipika Goyal, Chaya Levovitz, Giulia Siravegna, Dimitri Livitz et al. "Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers." Nature medicine 25, no. 9 (2019): 1415-1421.

"Here, in a prospective cohort of 42 patients with molecularly defined gastrointestinal cancers and acquired resistance to targeted therapy, direct comparison of postprogression cfDNA versus tumor biopsy revealed that cfDNA more frequently identified clinically relevant resistance alterations and multiple resistance mechanisms, detecting resistance alterations not found in the matched tumor biopsy in 78% of cases."

Gruber, Michaela, Ivana Bozic, Ignaty Leshchiner, Dimitri Livitz, Kristen Stevenson, Laura Rassenti, Daniel Rosebrock et al. "Growth dynamics in naturally progressing chronic lymphocytic leukaemia." Nature 570, no. 7762 (2019): 474-479.

"Each growth pattern was associated with marked differences in genetic composition, the pace of disease progression and the extent of clonal evolution. ... we found that dynamic changes in the disease course of CLL were shaped by the genetic events that were already present in the early slow-growing stages. Finally, by analysing the growth rates of subclones compared with their parental clones, we quantified the growth advantage conferred by putative CLL drivers in vivo."

Dentro, Stefan C., Ignaty Leshchiner, Kerstin Haase, Maxime Tarabichi, Jeff Wintersinger, Amit G. Deshwar, Kaixian Yu et al. "Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes." Cell 184, no. 8 (2021): 2239-2254.

"We observe positive selection of subclonal driver mutations across most cancer types and identify cancer type-specific subclonal patterns of driver gene mutations, fusions, structural variants, and copy number alterations as well as dynamic changes in mutational processes between subclonal expansions."